17 results on '"van Oosterhout, M"'
Search Results
2. CAN AXIAL SPONDYLOARTHRITIS UNEQUIVOCALLY BE DIAGNOSED BY RHEUMATOLOGISTS IN PATIENTS WITH CHRONIC BACK PAIN OF LESS THAN TWO YEARS DURATION? MAIN RESULT OF THE SPONDYLOARTHRITIS CAUGHT EARLY (SPACE) COHORT.
- Author
-
Marques, M. L., Ramiro, S., Van Lunteren, M., Stal, R., Berg, I. J., Fagerli, K. Minde, Van Oosterhout, M., Exarchou, S., Ramonda, R., Van de Sande, M. G. H., Landewé, R. B. M., Van der Heijde, D., and Van Gaalen, F. A.
- Published
- 2023
- Full Text
- View/download PDF
3. Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study
- Author
-
Wevers-de Boer, K. V. C., Heimans, L., Visser, K., Kälvesten, Johan, Goekoop, R. J., van Oosterhout, M., Harbers, J. B., Bijkerk, C., Steup-Beekman, M., de Buck, M. P. D. M., de Sonnaville, P. B. J., Huizinga, T. W. J., Allaart, C. F., Wevers-de Boer, K. V. C., Heimans, L., Visser, K., Kälvesten, Johan, Goekoop, R. J., van Oosterhout, M., Harbers, J. B., Bijkerk, C., Steup-Beekman, M., de Buck, M. P. D. M., de Sonnaville, P. B. J., Huizinga, T. W. J., and Allaart, C. F.
- Abstract
Aim To assess whether in early (rheumatoid) arthritis (RA) patients, metacarpal bone mineral density (BMD) loss after 4 months predicts radiological progression after 1 year of antirheumatic treatment. Methods Metacarpal BMD was measured 4 monthly during the first year by digital X-ray radiogrammetry (DXR-BMD) in patients participating in the IMPROVED study, a clinical trial in 610 patients with recent onset RA (2010 criteria) or undifferentiated arthritis, treated according to a remission (disease activity scoreless than1.6) steered strategy. With Sharp/van der Heijde progression greater than= 0.5 points after 1 year (yes/no) as dependent variable, univariate and multivariate logistic regression analyses were performed. Results Of 428 patients with DXR-BMD results and progression scores available, 28 (7%) had radiological progression after 1 year. Independent predictors for radiological progression were presence of baseline erosions (OR (95% CI) 6.5 (1.7 to 25)) and early DXR-BMD loss (OR (95% CI) 1.5 (1.1 to 2.0)). In 366 (86%) patients without baseline erosions, early DXR-BMD loss was the only independent predictor of progression (OR (95% CI) 2.0 (1.4 to 2.9)). Conclusions In early RA patients, metacarpal BMD loss after 4 months of treatment is an independent predictor of radiological progression after 1 year. In patients without baseline erosions, early metacarpal BMD loss is the main predictor of radiological progression., Funding Agencies|Abbott
- Published
- 2015
- Full Text
- View/download PDF
4. THE YIELD OF REPEATED ASSESSMENTS IN CHRONIC BACK PAIN PATIENTS SUSPECTED OF EARLY AXIAL SPONDYLOARTHRITIS: TWO-YEAR DATA FROM THE SPONDYLOARTHRITIS CAUGHT EARLY (SPACE) COHORT.
- Author
-
Marques, M. L., Ramiro, S., Van Lunteren, M., Stal, R., Berg, I. J., Fagerli, K. Minde, Van Oosterhout, M., Exarchou, S., Ramonda, R., Van de Sande, M. G. H., Landewé, R. B. M., Van der Heijde, D., and Van Gaalen, F. A.
- Published
- 2023
- Full Text
- View/download PDF
5. Presence of multiple spondyloarthritis (SpA) features is important but not sufficient for a diagnosis of axial spondyloarthritis: data from the SPondyloArthritis Caught Early (SPACE) cohort.
- Author
-
Ez-Zaitouni, Z., Bakker, P. A. C., van Lunteren, M., Berg, I. J., Landewé, R., van Oosterhout, M., Lorenzin, M., van der Heijde, D., and van Gaalen, F. A.
- Abstract
Objectives: Concerns have been raised about overdiagnosis of axial spondyloarthritis (axSpA). We investigated whether patients with chronic back pain (CBP) of short duration and multiple SpA features are always diagnosed with axSpA by the rheumatologist, and to what extent fulfilment of the Assessment of SpondyloArthritis International Society (ASAS) axSpA criteria is associated with an axSpA diagnosis.Methods: Baseline data from 500 patients from the SPondyloArthritis Caught Early cohort which includes patients with CBP (≥3 months, ≤2 years, onset <45 years) were analysed. All patients underwent full diagnostic workup including MRI of the sacroiliac joints (MRI-SI) and radiograph of sacroiliac joints (X-SI). For each patient, the total number of SpA features excluding sacroiliac imaging and human leucocyte antigen B27 (HLA-B27) status was calculated.Results: Before sacroiliac imaging and HLA-B27 testing, 32% of patients had ≤1 SpA feature, 29% had 2 SpA features, 16% had 3 SpA features and 24% had ≥4 SpA features. A diagnosis of axSpA was made in 250 (50%) of the patients: 24% with ≤1 SpA feature, 43% with 2 SpA features, 62% with 3 SpA features and 85% with ≥4 SpA features. Of the 230 patients with a positive ASAS classification 40 (17.4%) did not have a diagnosis of axSpA. HLA-B27 positivity (OR 5.6; 95% CI 3.7 to 8.3) and any (MRI-SI and/or X-SI) positive imaging (OR 34.3; 95% CI 17.3 to 67.7) were strong determinants of an axSpA diagnosis.Conclusions: In this cohort of patients with CBP, neither the presence of numerous SpA features nor fulfilment of the ASAS classification criteria did automatically lead to a diagnosis axSpA. Positive imaging was considered particularly important in making a diagnosis of axSpA. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
6. Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study.
- Author
-
Boer, K V C Wevers-de, Heimans, L, Visser, K, Kälvesten, J, Goekoop, R J, van Oosterhout, M, Harbers, J B, Bijkerk, C, Steup-Beekman, M, de Buck, M P D M, de Sonnaville, P B J, Huizinga, T W J, Allaart, C F, and Wevers-de Boer, K V C
- Abstract
Aim: To assess whether in early (rheumatoid) arthritis (RA) patients, metacarpal bone mineral density (BMD) loss after 4 months predicts radiological progression after 1 year of antirheumatic treatment.Methods: Metacarpal BMD was measured 4 monthly during the first year by digital X-ray radiogrammetry (DXR-BMD) in patients participating in the IMPROVED study, a clinical trial in 610 patients with recent onset RA (2010 criteria) or undifferentiated arthritis, treated according to a remission (disease activity score<1.6) steered strategy. With Sharp/van der Heijde progression ≥0.5 points after 1 year (yes/no) as dependent variable, univariate and multivariate logistic regression analyses were performed.Results: Of 428 patients with DXR-BMD results and progression scores available, 28 (7%) had radiological progression after 1 year. Independent predictors for radiological progression were presence of baseline erosions (OR (95% CI) 6.5 (1.7 to 25)) and early DXR-BMD loss (OR (95% CI) 1.5 (1.1 to 2.0)). In 366 (86%) patients without baseline erosions, early DXR-BMD loss was the only independent predictor of progression (OR (95% CI) 2.0 (1.4 to 2.9)).Conclusions: In early RA patients, metacarpal BMD loss after 4 months of treatment is an independent predictor of radiological progression after 1 year. In patients without baseline erosions, early metacarpal BMD loss is the main predictor of radiological progression. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
7. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
- Author
-
Heimans, L., Wevers-de Boer, K. V. C., Visser, K., Goekoop, R. J., van Oosterhout, M., Harbers, J. B., Bijkerk, C., Speyer, I., de Buck, M. P. D. M., de Sonnaville, P. B. J., Grillet, B. A. M., Huizinga, T. W. J., and Allaart, C. F.
- Abstract
Objectives To assess which treatment strategy is most effective in inducing remission in early (rheumatoid) arthritis. Methods 610 patients with early rheumatoid arthritis (RA 2010 criteria) or undifferentiated arthritis (UA) started treatment with methotrexate (MTX) and a tapered high dose of prednisone. Patients in early remission (Disease Activity Score <1.6 after 4 months) tapered prednisone to zero and those with persistent remission after 8 months, tapered and stopped MTX. Patients not in early remission were randomised to receive either MTX plus hydroxychloroquine plus sulfasalazine plus low-dose prednisone (arm 1) or to MTX plus adalimumab (ADA) (arm 2). If remission was present after 8 months both arms tapered to MTX monotherapy; if not, arm 1 changed to MTX plus ADA and arm 2 increased the dose of ADA. Remission rates and functional and radiological outcomes were compared between arms and between patients with RA and those with UA. Results 375/610 (61%) patients achieved early remission. After 1 year 68% of those were in remission and 32% in drug-free remission. Of the randomised patients, 25% in arm 1 and 41% in arm 2 achieved remission at year 1 (p<0.01). Outcomes were comparable between patients with RA and those with UA. Conclusions Initial MTX and prednisone resulted in early remission in 61% of patients with early (rheumatoid) arthritis. Of those, 68% were in remission and 32% were in drug-free remission after 1 year. In patients not in early remission, earlier introduction of ADA resulted in more remission at year 1 than first treating with disease-modifying antirheumatic drug combination therapy plus prednisone. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
8. Simplified versions of the original disease activity score: validation in the BeSt trial.
- Author
-
Koevoets, R., Klarenbeek, N. B., Güler-Yüksel, M., van Oosterhout, M., van Krugten, M. V., Kerstens, P. J. S. M., Huizinga, T. W. J., Dijkmans, B. A. C., van der Heijde, D. M. F. M., and Allaart, C. F.
- Abstract
Objective To evaluate three disease activity score (DAS) alternatives without the Ritchie articular index (RAI). To compare the use of patient global assessment (PGA) of disease activity versus global assessment of health (GH) in DAS, DAS alternatives and DAS28. Methods Data from the BeSt study were used, a treatment strategy trial in early rheumatoid arthritis patients aiming at a DAS ⩽2.4.DAS alternatives were DAS 0-1, with the RAI (0-3) reduced to a no-yes (0-1) score, DAS tender joint count 53 (DAS TJC53), with a 0-1 TJC in 53 separate joints and DAS TJC44 in 44 joints. Correlation patterns, mean difference from original DAS, classification differences in disease activity level and patient percentages with radiological damage progression per level were determined for all scores. Results In the majority of patients the scores were equal and correlation was high. Mean difference with the DAS at year 1 was -0.03 for DAS 0-1, 0.18 for DAS TJC53 and 0.11 for DAS TJC44. Classification agreement between scores was high (k year 1 0.76-0.98). Patient percentages with joint damage progression were similar for all scores. DAS, DAS alternative and DAS28 perform similarly using either PGA or GH. Conclusion DAS without the RAI perform comparably to the original DAS and may be chosen as alternatives. PGA can replace GH in the DAS, the alternatives and DAS28. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
9. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNFα and IL18 but not CXCL12.
- Author
-
van Oosterhout, M., Levarht, E. W. N., Sont, J. K., Huizinga, T. W. J., Toes, R. E. M., and van Laar, J. M.
- Published
- 2005
- Full Text
- View/download PDF
10. High dose chemotherapy and syngeneic stem cell transplantation in a patient with refractory rheumatoid arthritis: poor response associated with persistence of host autoantibodies and synovial abnormalities.
- Author
-
van Oosterhout, M., Verburg, R. J., Levarht, E. W. N., Moolenburgh, J. D., Barge, R. M., Fibbe, W. E., and van Laar, J. M.
- Published
- 2005
- Full Text
- View/download PDF
11. Determinants of radiographic progression in early psoriatic arthritis: insights from a real-world cohort.
- Author
-
Koc GH, Kok MR, do Rosario Y, Luime JJ, Tchetverikov I, Kasiem FR, Korswagen LA, Bijsterbosch J, Goekoop-Ruiterman YPM, van Oosterhout M, Baudoin P, Kok P, Dolhain RJEM, and Vis M
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Aged, Severity of Illness Index, Cohort Studies, Arthritis, Psoriatic diagnostic imaging, Arthritis, Psoriatic diagnosis, Arthritis, Psoriatic epidemiology, Disease Progression, Radiography
- Abstract
Objective: Persistent articular inflammation in psoriatic arthritis (PsA) is associated with radiographic damage. Despite advances in diagnosis and therapy, radiographic structural damage remains prevalent in PsA. To elucidate this topic, we studied which baseline clinical characteristics determine radiographic progression., Methods: For this analysis, data were used from DEPAR (Dutch South West Psoriatic Arthritis) Study, a real-world cohort of patients with newly diagnosed PsA. Radiographic changes were assessed using the modified Total Sharp/van der Heijde Score (mTSS) for PsA. Univariable-multivariable mixed-effects negative binomial regression analysis was applied to define baseline predictors for radiographic progression over time., Results: The study included 476 patients with early PsA with 1660 hand and feet radiographs from four different time points (baseline, first, second and third year). The progressive group (n=71) had a higher mTSS compared with the non-progressive group (n=405) at diagnosis (17 (3-36) vs 0 (0-1)). A comparison of the two groups revealed that the progressive group had significantly older (59 (12) vs 49 (13)) and a higher rate of the presence of swollen joints (93% vs 78%) at diagnosis. Multivariable analysis identified age (incidence rate ratio (IRR)=1.10, p=0.000), sex (female) (IRR=0.48, p=0.043) and baseline mTSS (IRR=1.11, p=0.000) as significant determinants of radiographic change over time. For the progressive subset, additionally, the multivariable analysis highlighted baseline Disease Activity in PSoriatic Arthritis (IRR=1.05, p=0.006) and swollen joint count (IRR=1.07, p=0.034) as predictors., Conclusions: According to this real-world cohort, patients with early PsA exhibit minimal radiographic progression under current treatment protocols. This study indicates that while old age and initial radiographic damage predict progression, female sex confers a protective effect on it. Furthermore, disease activity score and swollen joints emerged as predictors for radiographic changes during the follow-up in progressive patients., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
12. Window of opportunity in psoriatic arthritis: the earlier the better?
- Author
-
Snoeck Henkemans SVJ, de Jong PHP, Luime JJ, Kok MR, Tchetverikov I, Korswagen LA, van der Kooij SM, van Oosterhout M, Baudoin P, Bijsterbosch J, van der Kaap JH, van der Helm-van Mil AHM, and Vis M
- Subjects
- Humans, Female, Treatment Outcome, Delayed Diagnosis, Back Pain, Arthritis, Psoriatic diagnosis, Arthritis, Psoriatic drug therapy, Arthritis, Psoriatic epidemiology, Antirheumatic Agents therapeutic use
- Abstract
Objectives: To investigate whether there is a window of opportunity for psoriatic arthritis (PsA) patients and to assess which patient characteristics are associated with a longer diagnostic delay., Methods: All newly diagnosed, disease-modifying antirheumatic drug-naïve PsA patients who participated in the Dutch southwest Early PsA cohoRt and had ≥3 years of follow-up were studied. First, total delay was calculated as the time period between symptom onset and PsA diagnosis made by a rheumatologist and then split into patient and physician delays. The total delay was categorised into short (<12 weeks), intermediate (12 weeks to 1 year) or long (>1 year). These groups were compared on clinical (Minimal Disease Activity (MDA) and Disease Activity index for PSoriatic Arthritis (DAPSA) remission) and patient-reported outcomes during 3 years follow-up., Results: 708 PsA patients were studied of whom 136 (19%), 237 (33%) and 335 (47%) had a short, intermediate and long total delay, respectively. Patient delay was 1.0 month and physician delay was 4.5 months. Patients with a short delay were more likely to achieve MDA (OR 2.55, p=0.003) and DAPSA remission (OR 2.35,p=0.004) compared with PsA patients with a long delay. Patient-reported outcomes showed numerical but non-significant differences between the short and long delay groups. Female patients and those presenting with enthesitis, chronic back pain or normal C-reactive protein (CRP) had a longer delay., Conclusions: In PsA, referral and diagnosis within 1 year is associated with better clinical outcomes, suggesting the presence of a window of opportunity. The most gain in referral could be obtained in physician delay and in females, patients with enthesitis, chronic back pain or normal CRP., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
13. Construct validity and responsiveness of feasible composite disease activity measures for use in daily clinical practice in patients with psoriatic arthritis.
- Author
-
Kasiem FR, Kok MR, Luime JJ, Tchetverikov I, Korswagen LA, Denissen NHAM, Goekoop-Ruiterman YPM, van Oosterhout M, Fodili F, Hazes JMW, Tillett W, and Vis M
- Subjects
- Humans, Severity of Illness Index, Reproducibility of Results, Patient Reported Outcome Measures, Arthritis, Psoriatic diagnosis
- Abstract
Objective: There is a need for a widely accepted comprehensive disease activity measure for use in daily practice in patients with psoriatic arthritis (PsA). For this reason, the 3-item Visual Analogue Scale (3VAS) and 4-item Visual Analogue Scale (4VAS) were developed. This study aimed to test construct validity and responsiveness of the 3VAS and 4VAS in a population of patients with newly diagnosed PsA receiving usual care., Methods: Components of the 3VAS (physician global, patient global, patient skin) and 4VAS (physician global, patient pain, patient joint, patient skin) were scored on 0-10 VAS scales. Agreement of low disease activity (LDA) state between 3VAS/4VAS and other composite measures was tested using Venn diagrams. Construct validity and responsiveness (3-month interval) were assessed using Spearman correlation coefficients and standardised response means (SRM) with effect sizes (ES), respectively, following hypothesis generation. Both 3VAS/4VAS were also compared with several patient-reported outcome measures., Results: Data from 629 patients were used. Both 3VAS (ES=0.48, SRM 0.52) and 4VAS (ES=0.48, SRM=0.50) showed responsiveness similar to Disease Activity in PSoriatic Arthritis (DAPSA) and Disease Activity Score-28 (DAS28). Both measures had a strong correlation with DAPSA (r=0.80-0.87), Psoriatic Arthritis Disease Activity Score (PASDAS) (r=0.89) and Routine Assessment of Patient Index Data 3 (RAPID3) (r=0.84-0.92). 3VAS and 4VAS had the highest agreement with PASDAS in categorising patients to LDA at 12 months., Conclusion: This is the first study assessing the performance of the 3VAS and 4VAS in an observational cohort of patients with early PsA. Both measures have promising performance characteristics, showing strong correlations and good discrimination with existing composite measures. The 4VAS may be the preferred version with better face validity., Competing Interests: Competing interests: WT has received research funding, consulting or speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, GSK, MSD, Novartis, Ono Pharma, Pfizer and UCB., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
14. Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment.
- Author
-
Heckert SL, Bergstra SA, Goekoop-Ruiterman YPM, Güler-Yüksel M, Lems WF, Matthijssen XME, van Oosterhout M, Huizinga TWJ, and Allaart CF
- Subjects
- Humans, Inflammation drug therapy, Radiography, Edema, Drug Therapy, Combination, Arthritis, Rheumatoid complications, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid diagnostic imaging
- Abstract
Objectives: To investigate whether in rheumatoid arthritis (RA) frequency of local joint inflammation is associated with radiographic joint damage progression in that joint., Methods: Data from 473 patients with RA and available radiographs from the BeSt study were used. Patients were treated to target (Disease Activity Score of ≤2.4) for a median of 10 years. At each study visit every 3 months, joints were assessed for swelling and tenderness. Radiographs of hands and feet were made yearly. A generalised linear mixed model was used to assess the association between the percentage of study visits at which clinical inflammation was observed in a joint (cumulative inflammation) and radiographic joint damage in that same joint. Clinical inflammation was primarily defined as joint swelling (with or without joint tenderness). For secondary analyses, we also investigated joint tenderness without joint swelling. Damage was measured as the percentage of the maximum possible Sharp-Van der Heijde score in a particular joint., Results: Cumulative local joint swelling was associated with local progression of radiographic damage in the same joint (β=0.14, 95% CI 0.13 to 0.15). This association was also found in a subset of joints that were swollen at least once. Cumulative local joint tenderness without concurrent local joint swelling was less strongly associated with local radiographic joint damage progression (β=0.04, 95% CI 0.03 to 0.05)., Conclusions: In RA, long-term cumulative local joint inflammation is associated with joint damage progression in the same joint., Competing Interests: Competing interests: The original BeSt study was funded by a research grant from the Dutch College of Health Insurances (OG 99-026) with additional funding from Schering-Plough BV and Centocor. The authors, not the sponsors, were responsible for the study design, the collection, analyses and interpretation of all data, the writing of this article and the decision to publish., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
15. Evaluating quality of care in rheumatoid arthritis: the patient perspective.
- Author
-
Mahmood S, van Oosterhout M, de Jong S, Landewé R, van Riel P, and van Tuyl LHD
- Abstract
Competing Interests: Competing interests: RL declares to have the following disclosures: Consultation or participation in advisory boards: Abbott/AbbVie, Ablynx, AmGen, AstraZeneca, Bristol-Myers Squibb, Celgene, Janssen (formerly Centocor), Galapagos, GlaxoSmithKline, Novartis, Novo Nordisk, Merck, Pfizer, Roche, Schering-Plough, TiGenix, UCB and Wyeth; Research grants: Abbott, AmGen, Centocor, Novartis, Pfizer, Roche, Schering-Plough, UCB and Wyeth; Speaker fees: Abbott/AbbVie, AmGen, Bristol-Myers Squibb, Janssen (formerly Centocor), Merck, Pfizer, Roche, Schering-Plough, UCB and Wyeth. RL is Director of Rheumatology Consultancy BV, which is a registered company under Dutch law. PvR declares to have the following disclosures: Grants: AbbVie, Roche, Pfizer, MSD and UCB. SdJ and MvO are employees of one of the main funders of this project, Reumafonds (the Dutch Arthritis Foundation).
- Published
- 2017
- Full Text
- View/download PDF
16. Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort.
- Author
-
Turina MC, Yeremenko N, van Gaalen F, van Oosterhout M, Berg IJ, Ramonda R, Lebre CM, Landewé R, and Baeten D
- Abstract
Introduction: Decreasing the diagnostic delay in axial spondyloarthritis (axSpA) remains a major challenge. Here, we assessed the value of serum inflammatory biomarkers to distinguish early axSpA from other pathologies in a large cohort of patients referred with early back pain., Methods: Serum c reactive protein (CRP), erythrocyte sedimentation rate (ESR) and calprotectin were determined in the SPondyloArthritis Caught Early (SPACE) cohort (n=310), an early back pain inception cohort. Additionally, explorative serum biomarkers derived from the literature (interleukin-27 (IL-27), human β-defensin-2 (hBD-2) and lipcolin-2 (LCN-2)) were determined by ELISA in full-blown patients with ankylosing spondylitis (AS) (n=21) and healthy controls (n=20)., Results: Serum CRP and ESR levels were not elevated in early axSpA versus 'control' back pain patients. Serum calprotectin was elevated in early axSpA versus controls (p=0.01) but failed to identify early axSpA at the individual level (positive predictive value of 38.7%). As to explorative biomarkers, serum levels of IL-27 were not detectable, and hBD-2 and LCN-2 serum levels were not elevated in full-blown AS versus healthy controls (p=0.572, p=0.562, respectively). Therefore, these markers were not further determined in the SPACE cohort., Conclusions: None of the candidate serum inflammatory markers were useful as diagnostic markers in the early phase of axSpA., Competing Interests: MCT was supported by an unrestricted fellowship from Janssen and DB was supported by a VICI grant from The Netherlands Organization for Scientific Research (NWO), by a Consolidator Grant from the European Research Council (ERC), and by a grant from the Dutch Arthritis Foundation (Reumafonds). NY, FvG, MvO, IJB, RR, CL and RL have no conflict of interests.
- Published
- 2017
- Full Text
- View/download PDF
17. Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study.
- Author
-
Akdemir G, Verheul MK, Heimans L, Wevers-de Boer KV, Goekoop-Ruiterman YP, van Oosterhout M, Harbers JB, Bijkerk C, Steup-Beekman GM, Lard LR, Huizinga TW, Trouw LA, and Allaart CF
- Abstract
Objectives: To identify predictive factors of radiological progression in early arthritis patients treated by remission-steered treatment., Methods: In the IMPROVED study, 610 patients with early rheumatoid arthritis (RA) or undifferentiated arthritis (UA) were treated with methotrexate (MTX) and a tapered high dose of prednisone. Patients in early remission (disease activity score (DAS) <1.6 after 4 months) tapered prednisone to zero. Patients not in early remission were randomised to arm 1: MTX plus hydroxychloroquine, sulfasalazine and prednisone, or to arm 2: MTX plus adalimumab. Predictors of radiological progression (≥0.5 Sharp/van der Heijde score; SHS) after 2 years were assessed using logistic regression analysis., Results: Median (IQR) SHS progression in 488 patients was 0 (0-0) point, without differences between RA or UA patients or between treatment arms. In only 50/488 patients, the SHS progression was ≥0.5: 33 (66%) were in the early DAS remission group, 9 (18%) in arm 1, 5 (10%) in arm 2, 3 (6%) in the outside of protocol group. Age (OR (95% CI): 1.03 (1.00 to 1.06)) and the combined presence of anticarbamylated protein antibodies (anti-CarP) and anticitrullinated protein antibodies (ACPA) (2.54 (1.16 to 5.58)) were independent predictors for SHS progression. Symptom duration <12 weeks showed a trend., Conclusions: After 2 years of remission steered treatment in early arthritis patients, there was limited SHS progression in only a small group of patients. Numerically, patients who had achieved early DAS remission had more SHS progression than other patients. Positivity for both anti-CarP and ACPA and age were independently associated with SHS progression., Trial Registration Numbers: ISRCTN Register number 11916566 and EudraCT number 2006 06186-16.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.